RecruitingNCT06899581

Gut Health in Children With Cancer

Monitor Gut Health in Children Undergoing Treatment for Acute Myeloid Leukaemia Treatment: Case-control Study


Sponsor

Great Ormond Street Hospital for Children NHS Foundation Trust

Enrollment

40 participants

Start Date

Jan 30, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

The purpose of this study is to observe the impact leukaemia treatment has on gut health (microbiomes) and how quickly the gut health recovers after leukamia treatment. The gut microbiome has a number of important functions not only in the gut but within the whole body. Changes to your child's nutritional status throughout treatment may affect how well they recover from treatment. This study will monitor the impact of feeding and nutrition on nutritional status and gut health in young people undergoing treatment for leukaemia. The measurements needed to observe nutritional and gut microbiomes will occur when your child attends their routine medical appointments at Great Ormond Street Hospital. Medical treatment uses chemicals to kill leukaemia cells. The type of medications used in the treatment of leukaemia can damage the gut resulting in inflammation call mucositis. This stops the gut from working and sometimes nutrition has to be provided via a feeding tube or intravenous. Chemotherapy, mucositis and intravenous nutrition all have an impact on the gut. Little is know how the gut health recovers after treatment for leukaemia. This will be the first study to specifically monitor the impact of feeding and nutritional on gut health in children undergoing treatment for leukaemia. By understanding what changes are occurring to your child's nutritional status and gut halth during treatment and during recovery will help to develop guidelines for healthcare professionals to support optimal gut health recovery.


Eligibility

Min Age: 1 MonthMax Age: 16 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at gut health (the balance of bacteria in the digestive system) in children who have certain types of cancer — specifically AML (a type of leukemia), HLH (a rare immune disorder), or Burkitt lymphoma. Researchers want to understand how cancer and its treatment affect the gut. **You may be eligible if...** - You are between 0 and 16 years old - You have been diagnosed with AML, HLH, or Burkitt lymphoma - You (or your guardian) has agreed to participate **You may NOT be eligible if...** - You are 17 or older (those patients are treated in a separate unit) - You have an inflammatory bowel disease like Crohn's disease or ulcerative colitis - You were previously treated with chemotherapy at a different hospital Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTEnteral nutrition Food Derived Ingredient

For this case-control analysis, children with AML will be matched to cancer-free controls for age, sex and race. No antibiotics for 6 months. In collaboration with Professor Konstantinos Gerasimidis Professor of Clinical Nutrition School of Medicine. University of Glasgow. Healthy children have been recruited from the community via poster and social media advertisement. The whole bowel movement was collected in a disposable stool collection kit and stored in a benchtop freezer provided to study participants. Researcher defrosted the sample, homogenised it with mechanical kneading and aliquots were stored in -80. Cases: children with AML: Stool specimens will be obtained at three predefined time points for microbiome analysis: baseline start of AML treatment (within 2 weeks of admission); after induction chemotherapy initiation (6-8weeks); recovery phase 6-8 months.


Locations(1)

Great Ormond Street Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06899581


Related Trials